A cost analysis of hemodialysis and peritoneal dialysis for the management of end-stage renal failure at an academic hospital, Pretoria, South Africa by Makhele, Letlhogonolo et al.
Makhele, Letlhogonolo and Matlala, Moliehi and Sibanda, Mncengeli and 
Martin, Antony P. and Godman, Brian (2019) A cost analysis of 
hemodialysis and peritoneal dialysis for the management of end-stage 
renal failure at an academic hospital, Pretoria, South Africa. 
PharmacoEconomics - Open. ISSN 2509-4254 , 
http://dx.doi.org/10.1007/s41669-019-0124-5
This version is available at https://strathprints.strath.ac.uk/66939/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
Vol.:(0123456789)
PharmacoEconomics - Open 
https://doi.org/10.1007/s41669-019-0124-5
ORIGINAL RESEARCH ARTICLE
A Cost Analysis of Haemodialysis and Peritoneal Dialysis 
for the Management of End‑Stage Renal Failure At an Academic 
Hospital in Pretoria, South Africa
Letlhogonolo Makhele1 · Moliehi Matlala1 · Mncengeli Sibanda1 · Antony P. Martin2,3 · Brian Godman1,2,4,5 
 
© The Author(s) 2019
Abstract
Background Haemodialysis (HD) and peritoneal dialysis (PD) are commonly used treatments for the management of patients 
with end-stage renal disease (ESRD). The costs of managing these patients have grown in recent years with increasing rates 
of non-communicable diseases, which will adversely impact on national health budgets unless addressed. Currently, there 
is limited knowledge of the costs of ESRD within the public healthcare system in South Africa.
Objective The aim of this study was to examine the direct costs of HD and PD in South Africa from a healthcare provider’s 
perspective.
Methods A prospective, observational study was undertaken at a leading public hospital in South Africa. A micro-costing 
approach was applied to estimate healthcare costs using 46 adult patients with ESRD who had been receiving HD and PD 
for at least 3 months.
Results The highest proportion of patients (35%) were aged 40–50 years. Patients aged 29–39 years were mostly on HD 
(28% vs. 21% on PD) while those aged 51–59 years mostly used PD (29% vs. 16% on HD). The average age of patients on 
HD and PD were 41 and 42 years, respectively. Variable costs (HD: US$172, 359.15; PD: US$20, 488.79) were found to be 
the biggest cost drivers for both treatment modalities. The annual cost of HD per patient (US$205, 681.40) was higher than 
PD (US$25, 282.00 per patient), even though the diference was not statistically signiicant (p = 0.175).
Conclusion HD costs more than PD from the provider’s perspective. These cost estimates may be useful for carrying out 
future cost-efectiveness and cost-utility analyses in South Africa.
Key Points for Decision Makers 
This is the irst study in South Africa that compares the 
cost of diferent types of dialysis in the public healthcare 
system, with the study highlighting the biggest cost driv-
ers for haemodialysis (HD) and peritoneal dialysis (PD).
The indings demonstrate that HD is more expensive 
than PD from a provider’s perspective in South Africa.
Costs estimates found in this study can be used to inform 
future economic analyses and policies in combination 
with additional clinical and epidemiological studies to 
improve resource allocation for patients with kidney 
disease within a universal healthcare system.
1 Introduction
The number of patients with chronic kidney disease (CKD) 
is increasing worldwide, with CKD now seen as a global epi-
demic enhanced by increasing rates of diabetes and hyper-
tension [1–3]. The World Health Organization (WHO) esti-
mated that there were 220 million people globally with CKD 
in 2012 [1]. This is a concern as it is believed currently only 
a few countries are able to fully meet the medical needs of 
these patients [4]. This situation will get worse unless this is 
addressed as a result of increasing rates of hypertension and 
diabetes mellitus, especially in lower and middle-income 
countries (LMICs), which includes countries in sub-Sahara 
Africa [5–8]. In 2013, the incidence of kidney disease was 
estimated at 10% in Africa and 8–16% globally [9], although 
others have suggested the prevalence of CKD in sub-Sahara 
Africa is 13.9% [10]. As a result of increases in CKD, deaths 
due to CKD increased by 67% from 1999 to 2006 in South 
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Africa alone [11]. Deaths due to CKD are expected to rise 
further in South Africa with rising rates of obesity and 
hypertension [6, 12]. It is estimated that by 2030 > 70% of 
patients worldwide with end-stage renal disease (ESRD) will 
be in developing countries unless key issues and concerns 
are addressed [13].
Chronic kidney disease (CKD) is deined as kidney dam-
age or glomerular iltration rate (GFR) of < 60 mL/1.73 m 
for 3 months or more, irrespective of the cause [14]. When 
the gradual loss of kidney function reaches an advanced state 
of GFR < 15 mL/1.73 m, this is known as CKD stage 5 or 
ESRD [15, 16].
ESRD contributes signiicantly to morbidity and mortal-
ity, decreasing life expectancy, whilst its management con-
sumes an appreciable proportion of healthcare resources 
across countries including developing countries [13, 17–20]. 
It is estimated that up to 6% of the annual healthcare budget 
is spent on patients with ESRD in developed countries [20]. 
The optimal management of ESRD requires renal replace-
ment therapy in the form of either dialysis or renal transplan-
tation [9]. In the context of constrained budgets and rising 
patient demand for renal transplantation, many countries 
resort to dialysis as the initial preferred option for the man-
agement of ESRD [21].
As a result, dialysis programmes have shown an annual 
growth of between 6% and 12% over the past 20 years in 
developing countries [22]; however, growth rates are lower 
in Europe [23] and the US [24]. In view of the cost impli-
cations, only 4.5% of the world’s dialysis population are 
currently in Africa, which is far lower than the envisaged 
population actually requiring dialysis in developing coun-
tries [25]. This is concerning given the high prevalence of 
non-communicable diseases (NCDs) such as hypertension 
and diabetes in Africa [5, 7, 26–29], which has been exacer-
bated by increasing urbanisation and the adoption of modern 
lifestyles [30, 31].
Due to an increase in the prevalence and inancial bur-
den of ESRD, a number of countries have undertaken stud-
ies to determine the cost of renal transplantation as well as 
haemodialysis (HD) and peritoneal dialysis (PD) to inform 
future policies [13, 20, 21, 25, 32]. However, these studies 
have drawn diferent conclusions, primarily due to the eco-
nomic diferences between high-, middle- and low-income 
countries [25, 33]. For example, in a single-centre study 
undertaken in Sudan, it was found that HD was less expen-
sive when compared with renal transplantation, while the 
opposite was found in the United Kingdom and Mexico. 
However, the same study found that HD was more expensive 
when compared with renal transplantation in India [34]. A 
systematic review by Liu et al. involving 24 published papers 
found that PD is cost saving compared with in-centre HD 
therapy in most developed countries and some of the stud-
ied developing countries [35]. The disparities in the cost 
of HD and PD between high-income countries and LMICs 
might be attributed to a number of factors including lower 
wage rates among healthcare workers in low-income coun-
tries, which may result in lower costs of HD when compared 
with PD [33]. PD will generally also cost less in countries 
that have capacity for local manufacture of materials used 
in PD as well as in countries with a higher prevalence of 
patients undergoing PD owing to economies of scale [33]. 
This mix of factors will have an impact on overall dialysis 
costs in each country. Although PD is typically less expen-
sive compared with HD in many parts of the world [20, 35], 
the choice of dialysis modality may be inluenced by other 
factors such as patient-population considerations, inancial 
reimbursement, and incentives [33, 36].
In South Africa, life expectancy has increased signii-
cantly since the universal roll-out of antiretroviral therapy 
for the management of HIV, which was previously associ-
ated with high mortality [37–39]. This has resulted in an 
increasing proportion of ageing citizens and a concurrent 
increase in NCDs [40, 41]. In South Africa, only a minority 
of the population currently has medical insurance, with over 
80% of the population relying on the public sector for health 
services [39]. There is a commitment though by the South 
African government to change this by providing universal 
health care through the National Health Insurance (NHI) 
scheme. This will beneit all patients in the future.
South Africa had approximately 260 centres for dialysis 
and renal transplant in 2015; however, close to 90% of these 
were privately owned [42]. As a result, kidney transplant 
rates remain low in South Africa and patients are forced to 
endure long periods of dialysis while waiting for a transplant 
[10]. In the South African private medical sector, patients are 
more likely to be managed by automated HD. Conversely, 
patients in the public sector are more likely to be managed 
using PD due to the limited number of treatment centres 
[42]. In addition, dialysis in the public sector is reserved for 
patients who are eligible to receive a kidney transplant [10]. 
The management of CKD is further constrained by the fact 
that South Africa currently has only 2.1 nephrologists per 
million population compared with, for instance, 16 neph-
rologists per million population in the USA [43, 44].
The increased burden of NCDs in South Africa, includ-
ing patients with ESRD, has the potential to adversely 
impact health budgets and the allocation of scarce health-
care resources within the NHI scheme [39, 45, 46]. As such, 
the associated costs must be carefully managed. In view of 
this, the costs involved with treating chronic diseases such as 
CKD in the South African setting must be better understood.
Consequently, the objective of this study was to provide 
primary data on the cost of managing patients on either PD 
or HD in the public healthcare system in South Africa to 
inform economic evaluations as well as future health plan-
ning around patients with CKD in South Africa.
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2  Methods
2.1  Study Site and Population
The study was conducted in the renal unit at Dr George 
Mukhari Academic Hospital (DGMAH), located in the north 
of Pretoria. DGMAH was chosen for this study as it is one 
of the leading academic public hospitals in South Africa. 
The renal unit has a capacity of 22 beds, which comprises 
20 beds for inpatients and two beds for outpatients. At the 
time of the study, the hospital had two groups of patients 
receiving HD treatment three times a week on alternate days 
and data was collected daily from the patient iles to assess 
both groups. Patients on PD received monthly supplies; con-
sequently, data from this group of patients was collected 
monthly. According to the South African Renal Registry 
2015 annual report, the number of patients in South Africa 
currently on HD is 7529 and on PD is 1440 [42].
2.2  Framework and Study Design
This was a prospective observational study that assessed two 
cohorts (patients on either PD or HD). Data were collected 
from patient iles over a period of 12 weeks (June 2017 to 
August 2017) using a developed data collection instrument. 
The instrument was piloted in the hospital before use in the 
main study. All adult patients undergoing chronic HD and 
PD at the DGMAH renal unit for at least 3 months were 
included in the study. Patient ile numbers were used to 
ensure anonymity and maintain conidentiality of patient-
level data. A micro-costing approach was implemented to 
estimate the direct enumeration and costing of every item 
used for each individual patient.
2.3  Cost Data Identiication, Collection 
and Calculation
The perspective of this study was that of a healthcare pro-
vider, and the costs were calculated based on the provider’s 
expenditures. The costs were distinguished as initiation 
and maintenance costs for dialysis treatment. The initiation 
costs included the creation of a istula for access and other 
processes that are necessary to prepare the patient for this 
lifelong treatment. Maintenance costs included all the costs 
incurred during the treatment sessions.
Costs were further diferentiated between ixed, semi-
variable or variable costs. Costs that did not change over 
the short term were described as ixed costs and included the 
cost of the dialysis machine and maintenance. Non-medical 
ixed costs such as computers and beds were not included. 
Variable costs included electricity usage, laboratory tests, 
all materials and medicines that could be assigned directly 
to one HD session (see Box 1 in Appendix). For PD, vari-
able costs included medicines, dialysis solutions, labora-
tory tests and other consumables given to the patients every 
month (Box 1). Box 1 also contains other costs that were not 
included such as administrative costs, hotel or indirect costs, 
as well as informal home care costs, water and electricity 
costs for PD patients.
Patients’ files were reviewed and demographic data, 
comorbidities, as well as any relevant information that 
allowed for the determination of ixed, semi-variable and 
variable costs including medication costs of the two treat-
ment modalities were obtained from the facility. Medicines 
are typically procured by their generic name (INN—interna-
tional non-proprietary name), with prices obtained from the 
South African National Department of Health tender single 
exit price list. The medicines were provided free of charge 
by the provider hospital.
Water consumption of a single dialysis procedure was 
multiplied by the price per litre (including sewage charges 
and value added tax) to obtain the cost according to the local 
municipality charges. In order to obtain the cost of electric-
ity usage per month, all electrical appliances at the unit, 
watts consumed by each appliance, duration of usage per 
day, and the number of days the unit operated per month, 
were combined. The total electricity consumption was cal-
culated according to the standard local electricity provider’s 
levies. The cost of sterilisation per month was determined by 
multiplying the total number of sterilised packs by the unit 
price of each pack. Laboratory tests were calculated by add-
ing the costs together for all tests carried out on each patient. 
For all other medical consumables, such as sterile gloves, the 
prices were again obtained from the South African National 
Department of Health tender single exit price list.
Costs that increase stepwise (in a series of distinct 
stages) were described as semi-variable costs. Semi-var-
iable costs, including staf wages (Box 1), were obtained 
from DGMAH’s human resource department. In the case 
of dialysis machines, the depreciation per dialysis machine 
was calculated based on 8 years of functionality, which is 
typically their life span in the unit.
PD was provided at home; consequently, costs includ-
ing informal home care costs, water and electricity costs 
could not be calculated using our methodology and were 
not included (Box 1).
2.4  Data Analysis
Data were entered in Microsoft  Excel®, checked for accu-
racy and cleaned prior to analysis. The data were then 
transferred to  SPSS® full version 24 by the statistician 
and analysed descriptively by the authors. All costs were 
expressed in South African currency (Rands) then converted 
to United States Dollars (US$) using the exchange rate 
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(US$1.00 = R13.038) at the time of study [47]. All data for 
patient demographics (gender, age and race) and comorbidi-
ties were summarised as means frequency and percentages.
2.5  Ethics Approval and Consent to Participate
Ethical clearance was obtained from the Sefako 
Makgatho University Research Ethics Committee 
(SMUREC/P/68/2017) before the commencement of the 
study. In order to protect the identity of patients, a unique 
study number was assigned to each patient. Only the study 
number was used as a reference in the database. The names 
and identity numbers of the patients were excluded on 
the data collection forms. All data extraction forms were 
anonymised so that only the researcher had access to the 
patient information. Written permission was obtained from 
the CEO of DGMAH prior to the commencement of the 
study.
3  Results
3.1  Patient Demographics
Figure 1 shows that the highest proportion of the 46 patients 
studied were aged 40–50 years. All were Black South Afri-
can patients. Patients aged 29–39 years were mostly on HD, 
and those aged 51–59 years were mostly used PD. The mean 
average age of patients was 41 and 42 years for HD and 
PD, respectively, with a standard deviation of 8.4 and 11.71, 
respectively. In those receiving HD, 46% were females and 
54% males. There was an even split (50:50) for PD.
The majority of patients (HD 81%; PD 57%) had hyper-
tension as a comorbidity followed by HIV (HD 19%; PD 
21%). Heart failure was also common in PD patients (12%). 
Other comorbidities in patients receiving HD (13%) included 
diabetes (three patients) and epilepsy (one patient) (Table 1).
3.2  Treatment Costs
This section presents the costs associated for both treatment 
modalities. This includes the semi-variable costs broken 
down into maintenance and access costs, the variable costs 
for both modalities, the ixed costs (medical and non-med-
ical) and the costs of medicines, including the most costly 
medicines for both treatment modalities. All medicine costs 
were combined without looking speciically at one class, 
such as antibiotics, given the high rate of HIV among the 
studied population (Table 1). The costs of equipment for HD 
are included. Finally, the annual cost comparison between 
HD and PD is presented. Table 2 presents the semi-variable 
costs of both modalities. Staf salaries per month were simi-
lar for HD and PD.
Table 3 contains details of the variable costs for HD. 
Laundry costs, which included new cleaned linen sheets for 
patients, were the main contributors (50.6%). While labora-
tory costs accounted for 18.5% of these costs, haemo acid 
(6.15%) and bicarbonate (5.9%) also contributed to the vari-
able costs. Syringes, disposable masks and disposable plastic 
aprons contributed the least to the variable costs.
Table 4 summarises the variable costs for PD. Peritoneal 
dialysis solutions, namely Dianeal 1.5® and Dianeal 2.5® 
(US$392.36 each), contributed the most when compared 
with the total variable cost of PD. The contribution of labo-
ratory tests to overall variable costs was also high (25.9%), 
with gloves, needles and lignocaine contributing the least to 
the total cost of PD.
Tables 3 and 4 also present a detailed cost breakdown of 
variable costs, including one-of costs for istula access for 
both modalities. The percentage contribution of each vari-
able cost to total variable costs is also included. The monthly 
costs of laboratory tests (HD: US$2755.0; PD: US$490.4) 
accounted for an appreciable amount of the total costs for 
both modalities. The laboratory tests included urea and elec-
trolytes, full metabolic proile, creatinine, full blood count 
including platelets, Enzyme Linked Immunosorbent Assay 
(ELISA), hepatitis A, B and C and international normal-
ised ratio (INR). The cost of catheters had an appreciable 
impact on total variable costs for PD but not HD patients 
(HD: US$197.8; PD: US$197.8). Other variable costs that 
contributed to total costs included ultrasound for PD but 
not HD (HD: US$68.4; PD: US$68.84) and laundry for HD 
patients (US$7514.9).
In public sector hospitals in South Africa including 
DGMAH, HD patients attend therapy sessions up to three 
times a week, with each session typically lasting up to 4 h 
[48]. This is relected in the high variable costs for HD 
patients.
Table 5 includes the direct medical ixed costs of HD, 
which includes dialysis machine purchase costs, 5-year 
maintenance service costs and equipment depreciation costs. 
These costs are relected in Fig. 2.
3.3  Cost of Medicines
The average of seven medications per prescription for HD 
patients with an average cost of US$61.84 was lower than 
that of PD patients at an average of nine medications per 
prescription costing an average of US$319.85. Overall, the 
annual cost of medicines was US$742.33 for HD patients 
and US$3839.26 for PD patients (Fig. 2).
Table 6 highlights the ive most costly medicines used for 
both modalities and their associated costs.
Figure 2 illustrates that the annual cost for treating PD 
patients (US$25,282.39) was lower than that for treating HD 
patients (US$205,681.4), although this was not statistically 
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signiicant (p = 0.175). Variable costs (HD: US$172,359.15; 
PD: US$20,488.79) were the biggest cost drivers for both 
treatment modalities. Semi-variable costs also contributed 
signiicantly to the total cost for HD patients. The costs of 
medication (US$3839.26) for PD patients contributed a 
higher percentage to the total costs than that for HD patients 
(US$742.33).
4  Discussion
In this study, the majority of patients were on HD compared 
with PD, which was consistent with the recent South African 
Renal Registry Annual Report (HD: 71.2%, PD: 14%) [42] 
and the European Renal Association—European Dialysis 
Treatment Association Registry (ERA-EDT) 2015 (HD: 
66%, PD: 29%) [49]. These indings are also consistent with 
Jain et al., who reported that 12.4% of dialysis patients in 
developing countries were now on PD; although there was 
substantial variation between countries [50]. The reasons 
for the diferences could be largely based on socioeconomic 
factors such as access to sanitation [51]. There were also 
more males than females on treatment in our study, which 
relected the general gender distribution of patients on dialy-
sis in South Africa [42], Tanzania [13], Sudan [34], Euro-
pean countries [49] and the Cameroon [18].
The majority of patients in the study were also hyper-
tensive, comparable to the US where 84% of patients with 
stage 4–5 renal failure had hypertension [24]. Hypertension 
can either be the cause of the renal failure or it develops 
as a complication due to renal failure, with heart failure a 
complication of advanced renal disease [52]. In the US, the 
prevalence of heart failure is 63% in patients with CKD, 
whereas the prevalence of heart failure in our study was 
much lower for both modalities (HD: 3%, PD: 12%) [24]. 
The under-reporting of heart failure in our study may be due 
to the study’s sole reliance on patients’ iles for information 
rather than a lack of diagnosis of heart failure; however, we 
cannot say this with certainty, and we will be looking at this 
further in future research projects.
HIV was the third most common comorbidity of renal 
failure in our study. This is expected since HIV is highly 
prevalent in South Africa, endorsing the need to look closely 
at this co-morbidity, especially among patients in sub-Sahara 
Africa [41]. Renal failure in HIV can either be caused by 
direct infection of the kidney or as a result of antiretroviral 
drugs [53, 54]. However, due to insuicient information in 
the patients’ iles, it is unclear whether the patients acquired 
renal disease before or after they were diagnosed with HIV. 
Diabetes mellitus is another leading cause of renal failure 
[1]. However, this study found only three patients who were 
on HD had diabetes mellitus as a comorbidity. This is per-
haps not surprising as dialysis is not currently funded for 
these patients within the South African public healthcare 
systems, with a belief that scarce available resources are bet-
ter spent preventing CKD in these patients in the irst place 
with better management of their diabetes. Consequently, pro-
grammes to improve access to medicines and their use as 
Fig. 1  Age distribution for HD 
and PD
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Table 1  Comorbidities in patients on HD and PD
NB Patients can have more than one co-morbidity, HD Haemodialy-
sis, PD peritoneal dialysis
HD (n = 32) (%) PD 
(n = 14) 
(%)
Hypertension 81 57
HIV 19 21
Heart failure 3 12
Other 13 0
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part of chronic disease management programmes in patients 
with diabetes should help in this regard [39]. All patients in 
the renal unit received treatment for anaemia, which is not 
surprising as it is the most common complication of chronic 
renal failure.
Overall, patients on HD had more comorbidities than 
those on PD in our study, which is similar to the find-
ings of Chang et al. [20]. It is important to manage these 
comorbidities appropriately, including encouraging adher-
ence to prescribed medicines for NCDs, which is a concern 
in sub-Sahara Africa as this poses a considerable inancial 
burden to health systems [7, 29, 55–58]. For instance, the 
number of HD or PD sessions may increase per week if 
comorbidities are not managed adequately [59].
The average number of medicines per prescription was 
higher for PD patients (HD: 7; PD: 9). Similarly, the average 
Table 2  Semi-variable costs per month per patient
Currency conversion rate: 1 US Dollar (US$) = 13.07380 Rand (R)
Haemodialysis Peritoneal dialysis
Cost for 
maintenance 
(R)
Cost for access 
(R)
Cost (US$) Contribution to 
total semi-vari-
able costs (%)
Cost for 
maintenance 
(R)
Cost for access 
(R)
Cost (US$) Contribution to 
total semi-vari-
able costs (%)
Nursing assis-
tant
924.00 0.00 70.68 10.49 0.00 0.00 0.00 0.00
Dialysis nurse 2,700.00 0.00 206.52 30.67 0.00 0.00 0.00 0.00
Registrar 4,200.00 0.00 321.25 47.70 350.00 0.00 26.77 35.30
Nurse 0.00 28.25 2.16 0.32 28.25 28.50 4.34 5.72
Social worker 243.48 20.29 20.18 3.00 20.29 20.29 3.10 4.09
Phlebotomist 157.44 0.00 12.04 1.79 13.12 0.00 1.00 1.32
Anaesthesiology 
per hour
0.00 450.00 34.42 5.11 0.00 450.00 34.42 45.39
Dieticians 0.00 81.00 6.20 0.92 0.00 81.00 6.20 8.17
Table 3  Variable costs of 
haemodialysis per month per 
patient
Currency conversion rate: 1 US Dollar (US$) = 13.07380 Rand (R)
Variable Cost for mainte-
nance (US$)
Cost for 
access (US$)
Total cost (US$) Contribution to total 
variable costs (%)
Laundry 7514.90 0.0 7514.90 50.58
Laboratory test 2470.52 284.49 2755.01 18.54
Haemo acid 914.19 0.0 914.19 6.15
Bicarbonate 881.15 0.0 881.15 5.93
Bleach 568.23 0.0 568.23 3.82
Bloodlines 517.68 0.0 517.68 3.48
Clamp 461.50 3.20 464.70 3.13
Catheter 0.0 197.76 197.76 1.33
Electricity cost 159.71 0.0 159.71 1.07
Normal saline 500 mL 154.20 0.0 154.20 1.04
Water cost 137.35 0.0 137.35 0.92
0.94 Heparin 5000 IU 115.43 0.83 116.26 0.78
Sterile gloves 104.86 0.73 105.59 0.71
Adhesive wound plaster 89.77 0.0 89.77 0.60
IV giving set 73.47 0.0 73.47 0.49
Ultrasound 0.0 68.84 68.84 0.46
Needles 60.14 0.42 60.56 0.41
Syringe 5 cm3 40.75 0.0 40.75 0.27
Iron lab test 16.64 0.0 16.64 0.11
Disposable mask 11.79 0.0 11.79 0.08
Alcohol swabs 10.24 0.0 10.24 0.07
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cost per prescription was higher for PD versus HD patients, 
which was due mostly to the greater use of erythropoietin 
in the treatment of anaemia in PD patients, with erythro-
poietin dominating the medicine costs (Table 6). Medicines 
such as furosemide and doxazosin are used to treat the co-
morbidities of HD and PD patients. The higher prevalence 
of heart failure in PD patients may also have added to higher 
medicine costs (Fig. 2). This is similar to indings in the 
UK where erythropoietin was one of the main dialysis cost 
drivers [60]. This is because almost all patients on either 
HD or PD were prescribed medication to prevent anaemia. 
Having said this, at DGMAH there is limited use of eryth-
ropoietin among HD patients as they are closely monitored 
during their three sessions per week. At these sessions, the 
medical staf check for physical signs of anaemia as a routine 
Table 4  Variable costs of 
peritoneal dialysis per month 
per patient
Currency conversion rate: 1 US Dollar (US$) = 13.07380 Rand (R)
Variable costs Cost for mainte-
nance (US$)
Cost for access 
(US$)
Total cost (US$) Contribution to total 
variable costs (%)
Laboratory test 205.9 284.5 490.4 25.87
Dianeal 1.5  NC® 392.4 0 392.4 20.70
Dianeal 2.5  NC® 392.4 0 392.4 20.70
Mincap® 205.9 0 205.9 10.86
Catheter 0 197.8 197.8 10.43
K-Shield 137.5 0 137.5 7.25
Ultrasound 0 68.4 68.4 3.61
Iron lab test 5.5 0 5.5 0.29
Clamp 0 3.2 3.2 0.17
Heparin 0 0.8 0.8 0.04
Gloves 0 0.7 0.7 0.04
Needles 0 0.4 0.4 0.02
Lignocaine 0 0.2 0.2 0.01
Table 5  Fixed medical costs 
per year associated with dialysis 
machines
Currency conversion rate: 1 US Dollar (US$) = 13.07380 Rand (R)
Annual cost (R) Annual cost (US$) Proportion of 
the total cost 
(%)
Dialysis machine 138,326.79 10,580.46 65.18
Maintenance 46,214.72 3534.91 21.78
Equipment depreciation 27,665.40 2116.08 13.04
Total cost 212,206.91 16,231.45 100.00
Fixed costs (US$)
Cost of
medicaon (US$)
Semi-variable
costs (US$)
Variable costs
(US$)
HD $16,231.45 $742.33 $7,593.71 $1,72,359.15
PD $0.00 $3,839.26 $954.35 $20,488.79
0.00
20,000.00
40,000.00
60,000.00
80,000.00
1,00,000.00
1,20,000.00
1,40,000.00
1,60,000.00
1,80,000.00
2,00,000.00
U
S
$
Fig. 2  Annual cost comparison between HD and PD
Table 6  Five most costly medicines for both HD and PD per month
Currency conversion rate: 1 US Dollar (US$) = 13.07380 Rand (R)
Cost in Rands Cost in U$S
Erythropoietin 4000 IU 3848.20 294.34
Furosemide 500 mg 833.83 63.78
Doxazosin 301.50 23.06
Lopinavir/ritonavir 185.90 14.22
Fixed-dose combination 119.42 9.13
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check-up of dialysis and instigate appropriate prevention 
measures. This is not the case with PD treatment as it is 
home based.
The high cost of laboratory tests for both modalities 
(accounting for 18.5% of variable costs for HD patients and 
25.9% for PD patients—Tables 3 and 4) could be down to 
the current regulations for chronic renal dialysis patients in 
South Africa [61]. These mandate a number of tests in the 
management of patients on dialysis including urea and elec-
trolytes, a full metabolic proile, creatinine, full blood count 
plus platelets, ELISA, hepatitis A B and C and INR [61].
Overall, the direct cost of HD in our study was higher 
than the cost of PD from the provider’s perspective. This 
was the case in the initiation and maintenance phases of 
both modalities. This is similar to the indings of Berger 
et al. [32], Mushi et al. [13] and Chang et al. [20]. This 
is perhaps not surprising with HD hospital-based and PD 
home-based. The major cost drivers of dialysis treatment 
per month for both modalities were the variable costs 
(Fig. 2). As a result, the annual cost of HD (US$205,681.4) 
was appreciably higher than that of PD (US$25,282) even 
though this was not statistically significant (p = 0.175). 
Moosa et al. estimated the cost of dialysis at approximately 
US$15,297.8 per patient per annum at a conversion rate of 
US$1 to R13.0378, which is close but lower than our ind-
ings for PD patients at US$25,282 per patient/per annum 
(Fig. 2), which is encouraging [16]. As mentioned, accord-
ing to the South African Renal Registry 2015 annual report, 
the number of patients in South Africa on HD is 7529 and 
PD is 1440 [42]. Using the annual costs found in this study, 
it will cost US$1,548,575,260.6 to treat all patients on HD 
and US$36,406,646.0 for patients on PD. This is a concern 
given the current gross domestic product (GDP) (US$349.42 
billion) of South Africa [62] and the current medical need 
for all patients within the public healthcare system, includ-
ing new patients with ESRD. The cost ratio of HD/PD (7.79) 
was also higher than seen in a study by Okpechi et al., where 
this was 0.58 [25]. However, Abu-Aisha and Elamin [63] 
found that PD was more expensive than HD in most Sub-
Saharan countries as these countries did not have the inan-
cial capacity or infrastructure to locally manufacture PD 
solutions [25]. This has to be considered when reviewing 
resource use across diferent country settings.
Several assumptions were made in this study. For 
instance, when calculating staf costs for HD, it was assumed 
that each patient was seen by a physician for an hour per 
HD session and monitored over 4 h by the dialysis nurse. It 
was also assumed that the machine for HD was purchased 
on initiation; consequently, we did not include depreciation 
costs in the initiation costs for HD. However, the depre-
ciation costs and maintenance costs were included in the 
monthly variable costs. In addition, because micro-costing 
requires prospective data collection, but in this case, data 
were collected retrospectively in some HD patients because 
the data collector could only research one patient at a time, 
complete micro-costing for HD patients was impossible. 
As mentioned, there was also no discounting of costs. We 
realise this must be factored into any new analysis along-
side administrative costs, building costs, hotel and bed costs 
(Box 1) as well as indirect costs. In addition, as mentioned, 
informal home care costs, water and electricity costs were 
not included in PD costs (Box 1).
We are also aware that this study was carried out in only 
one public hospital in South Africa, albeit a major public 
hospital in South Africa, with a limited number of patients. 
Despite these limitations, we believe this study was able 
to provide primary data on the current costs for HD and 
PD in South Africa from a public provider’s perspective. 
We also believe this data can be combined with data from 
epidemiological studies, clinical studies, and other sources 
of information, to provide a foundation to enable broader 
health economic analyses such as cost-efectiveness and 
cost-utility analysis of the diferent treatment modalities to 
treat patients with ESRD in South Africa. These combined 
studies can subsequently be used to guide future decision 
making and planning for these patients in South Africa. This 
could also include programme budgeting and marginal anal-
ysis (PBMA) of diferent approaches to the prevention and 
earlier identiication of patients with renal disease to reduce 
future morbidity, mortality and costs [64–67].
5  Conclusion
The costs of HD are higher than PD from a hospital pro-
vider perspective in South Africa. This was mainly due to 
an increase in laundry costs and laboratory tests for treating 
patients with HD due to the high number of sessions (up 
to 12 a month), as well as purchasing and maintaining the 
dialysis equipment. These are considerations for the future 
as the Government in South Africa commits to providing 
universal healthcare for all patients through the NHI.
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• Haemo Acid, bicarbonate, normal saline, water and 
heparin costs
• Bleach
• Bloodlines
• Clamps, catheters, sterile gloves, disposable masks, 
alcohol swabs
• Electricity
• Adhesive wound plasters, IV giving set, needles and 
syringes
• Ultrasound
 
Costs not included in fixed costs (Table  5 and 
Fig.  2)
• Administrative costs
• Beds (cost of the beds)
• Building and hotel costs
• Reverse osmosis system
• Vital monitors
• ECG monitors
• Emergency trolleys
• Deibrillators
• Drip stands
• Dressing trolleys
• Overhead tables
• Computers, printers and desks in the unit
• Informal home care costs as well as water and elec-
tricity (PD patients)
Appendix
Box 1 Key annual cost items for patients (US$) including 
costs not included in the Tables
Fixed costs (medical)
• Dialysis machines including maintenance: 
US$16,231.45 (including depreciation—Table 5)
• Bed costs (for 22 beds): US$44,965.13
• RO system: US$15,000.00
• Aqua machine: US$10,171.49
• Vital monitors (2): US$2,192.09
• ECG: US$1,758.64
• Emergency trolley: US$893.38
• Deibrillator: US$397.61
• Drip stands (22): US$395.31
• Dressing trolley (3): US$217.00
 
Fixed costs (non-medical)
• Overhead Tables (22): US$3,168.01
• Computer for the ward: US$611.7
• Printer: US$191.16
• Desk: US$81.97
Semi-variable costs (details in Table 2)
• Nursing costs, phlebotomist costs
• Physicians including anaesthetists
• Social workers
• Dieticians
Variable costs (details in Tables 3 and 4)
• Laundry
• Costs of tests including laboratory costs and iron lab 
costs
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